EPO906 in Carcinoid and Other Neuroendocrine Tumors
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
This study will examine whether the new investigational drug EPO906, given by intravenous
infusion (IV directly into the vein), is effective in shrinking tumors and preventing the
growth of cells that cause metastatic carcinoid and other neuroendocrine tumors.